China pilot eyes easier marketing authorization

China flag
China flag

A pilot program to widen eligibility for drug marketing authorization approval by the China FDA will help small and innovative companies get drugs to market at a lower cost.

The Marketing Authorization Holder (MAH) pilot, recently approved by the State Council, allows researchers and smaller operations approved to apply for and hold China FDA approvals in the absence of in-house manufacturing facilities--marking a departure from the requirement, according to a note from law firm Ropes & Gray on the pilot.

The change, if adopted widely after the pilot ends in November 2018, will allow innovative drug developers to hire contract manufacturers and save them the expense of full-blown operations, the law firm noted.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

"The MAH system demonstrates China’s strong momentum to unleash innovation in the pharmaceutical sector," the law firm said. "Both local and foreign players should consider leveraging the regulatory flexibility of the pilot program to acquire or spin off assets and to utilize GMP-certified contract manufacturing arrangements. Contract manufacturers are also advised to revisit potential opportunities in the Chinese market."

Policymakers in China have expressed concern that drug development costs could lead to higher prices for approved innovative products developed locally. To give some breathing room, the MAH pilot allows firms life science development hubs the chance to qualify.

The rules state that an individual holder of marketing authorization must be a Chinese citizen, and some medicines are excluded.

- here's an update from Ropes & Gray


Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.